Compare ADMA Biologics Inc (ADMA) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Davita Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Davita Inc trades at $231.02 (market cap $15.04B). The key difference: Davita Inc is far larger — about 7.1× ADMA Biologics Inc's market cap, and Davita Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DVA | |
|---|---|---|
Market Cap | $2.13B | $15.04B |
Sector | Health | Health |
52-Week High | $20.38 | $235.71 |
52-Week Low | $7.60 | $103.87 |
Enterprise Value | $2.20B | $27.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
DaVita (DVA) trades at $234.31, showing modest daily decline but maintaining strong momentum near 52-week highs. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth continues with $13.64B in 2025, while net margins of 5.65% reflect steady profitability. Recent news highlights DVA's expansion in kidney care delivery and AI-driven scheduling improvements, positioning the company for continued growth in specialized healthcare services.
Investment outlook remains positive with analyst consensus favoring Buy ratings (39%) and price targets averaging $211. Key opportunities include expanding kidney care services and operational efficiencies, while risks involve high debt levels (65.55% debt-to-asset ratio) and healthcare regulatory pressures. Current valuation metrics (P/E 22.71, P/S 1.24) appear reasonable given growth prospects, though the stock trades above consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
